Drug
BTK Inhibitor
BTK Inhibitor is a pharmaceutical drug with 6 clinical trials. Currently 3 active trials ongoing.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
3(50%)
Phase Distribution
Ph phase_1
1
17%
Ph phase_2
2
33%
Ph phase_3
1
17%
Phase Distribution
1
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
6
all time
Status Distribution
Active(5)
Other(1)
Detailed Status
Recruiting3
Not yet recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
3
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)
Trials by Status
unknown117%
not_yet_recruiting233%
recruiting350%
Recent Activity
3 active trials
Showing 5 of 6
recruitingphase_1
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06675123
recruitingphase_3
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566
not_yet_recruiting
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06557304
recruiting
Current Status of BTKi Treatment for CLL/SLL in China
NCT06508684
not_yet_recruitingphase_2
A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
NCT06476899
Clinical Trials (6)
Showing 6 of 6 trials
NCT06675123Phase 1
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT06104566Phase 3
Global Trial in APG2575 for Patients With CLL/SLL
NCT06557304
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
NCT06508684
Current Status of BTKi Treatment for CLL/SLL in China
NCT06476899Phase 2
A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy
NCT05871684Phase 2
A Combination Study of CAR-T Therapy in r/r B-NHL
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6